DigestRedComo funciona
Red
/
Empresas
Ev
No verificado

Evaxion

Sobre qué escribimos

Anuncios brevesBiotecnologíaFinanzasGestión empresarial/Administración de EmpresasPublicidad/Marketing/Medios de comunicación/Comunicación

55 Comunicados de prensa

Ver todos los comunicados de prensa
12/11/2026
Biotecnología
Anuncios breves
Evaxion announce 2027 financial calendar
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
09/11/2026
Biotecnología
Anuncios breves
Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
06/11/2026
Biotecnología
Anuncios breves
New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
04/11/2026
Biotecnología
Anuncios breves
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
03/11/2026
Biotecnología
Anuncios breves
Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
30/10/2026
Biotecnología
Anuncios breves
Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
22/10/2026
Biotecnología
Anuncios breves
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
19/10/2026
Biotecnología
Anuncios breves
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
02/10/2026
Biotecnología
Anuncios breves
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
14/09/2026
Biotecnología
Anuncios breves
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0